The contract was awarded under the Clinical Research Support Services (CRSS) program of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.
Per the contract, PPD will provide support services for the NIAID/DAIDS-supported clinical research portfolio and other infectious diseases relevant to HIV-infected and at-risk populations, according to the company.
"Services includes site and laboratory assessments, site and laboratory audits, training and other site support activities. The contract is in transition and will be fully operational in mid-November," Patti McNamara, vice president, PPD told Outsourcing-Pharma.com.
PPD’s original contract with NIAID was awarded nearly 27 years ago. It was recently renewed in March of this year to cover a range of services, including monitoring therapeutic trials, prevention trials, and vaccines work, with the ultimate goal of an “AIDS-free generation,” Outsourcing-Pharma.com reported at the time.
"The PPD/NIAID relationship began in 1990 and has grown and matured over the years as NIAID has built their trust in PPD based on our strong clinical delivery," McNamara added. "PPD is currently supporting NIAID on three contracts to provide site-related services on a global basis."